补肾生血方防治化疗血液学毒性反应临床观察

随着肿瘤化疗方案应用进展,化疗已成为肿瘤临床综合治疗重要手段之一。但化疗药物所造成血液学毒性反应已严重影响化疗正常进行,从而导致临床疗效降低。据国外文献报道[1-3],与化疗中Ⅳ度血液学毒性反应有关的治疗相关性死亡率可达4%-21%。因此防治化疗药物所致的血液学毒性反应具有重要临床意义。     

Clinical Research of Compound Zhebei Granules for Increasing the Therapeutic Effect of Chemotherapy in Refractory Acute Leukemia Patients

Objective： To observe the effects of Compound Zhebei Granules （复方浙贝颗粒 CZG） in chemotherapy for refractory acute leukemia. Method： Using a randomized, double-blind and multi-central concurrent control clinical research project, the patients conformed with the diagnostic criteria, according to the drug randomized method, were divided into a CZG group and a control group. The patients of the two groups respectively took the observation drug or a placebo 3 days before chemotherapy, and the therapeutic effects were evaluated after one course of chemotherapy. According to the clinical research project, 137 patients were enrolled, including 71 cases in the CZG group and 66 cases in the control group. Results： The clinical complete remission （CR） rate was 42.3% in the CZG group with a total effective rate of 73.2%, and it was 25.8% in the control group with a total effective rate of 53.0%, showing a statistically significant difference between the two groups （P〈0.05）. Conclusion： CZG can increase the clinical remission rate for refractory acute leukemia during chemotherapy.